Q1 Earnings Estimate for Medpace Issued By Leerink Partnrs

Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) - Equities research analysts at Leerink Partnrs issued their Q1 2025 earnings estimates for Medpace in a report issued on Monday, March 24th. Leerink Partnrs analyst M. Cherny anticipates that the company will earn $3.03 per share for the quarter. Leerink Partnrs has a "Hold" rating on the stock. The consensus estimate for Medpace's current full-year earnings is $12.29 per share. Leerink Partnrs also issued estimates for Medpace's Q2 2025 earnings at $2.96 EPS, Q3 2025 earnings at $2.92 EPS, Q4 2025 earnings at $3.16 EPS, FY2025 earnings at $12.07 EPS, FY2026 earnings at $12.76 EPS, FY2027 earnings at $13.90 EPS and FY2028 earnings at $15.81 EPS.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its quarterly earnings data on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%.

Several other research firms have also recently weighed in on MEDP. Leerink Partners started coverage on shares of Medpace in a research note on Monday, March 24th. They set a "market perform" rating and a $330.00 target price for the company. Robert W. Baird increased their price target on Medpace from $354.00 to $362.00 and gave the company a "neutral" rating in a research note on Monday, January 27th. Nine equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat, Medpace presently has a consensus rating of "Hold" and a consensus price target of $376.30.

Remove Ads

Medpace Price Performance

Shares of MEDP stock traded down $4.25 on Wednesday, hitting $312.36. 343,137 shares of the stock traded hands, compared to its average volume of 298,736. The firm has a market cap of $9.52 billion, a price-to-earnings ratio of 24.73, a PEG ratio of 3.81 and a beta of 1.47. The firm has a 50 day simple moving average of $335.90 and a two-hundred day simple moving average of $339.15. Medpace has a 52 week low of $302.01 and a 52 week high of $459.77.

Institutional Investors Weigh In On Medpace

Hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. lifted its stake in Medpace by 1.0% in the fourth quarter. Vanguard Group Inc. now owns 2,570,770 shares of the company's stock worth $854,087,000 after acquiring an additional 25,704 shares during the period. Invesco Ltd. boosted its stake in shares of Medpace by 91.8% during the fourth quarter. Invesco Ltd. now owns 1,084,753 shares of the company's stock valued at $360,387,000 after purchasing an additional 519,186 shares in the last quarter. Wasatch Advisors LP increased its holdings in Medpace by 3.1% during the fourth quarter. Wasatch Advisors LP now owns 936,842 shares of the company's stock valued at $311,247,000 after buying an additional 28,161 shares during the period. State Street Corp raised its stake in Medpace by 7.2% in the third quarter. State Street Corp now owns 752,957 shares of the company's stock worth $251,337,000 after buying an additional 50,312 shares in the last quarter. Finally, Geode Capital Management LLC lifted its holdings in Medpace by 4.5% during the fourth quarter. Geode Capital Management LLC now owns 656,130 shares of the company's stock worth $218,031,000 after buying an additional 28,076 shares during the period. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.